A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer

BACKGROUND: Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose (RPTD) for the combination of capecitabine and...

Descripción completa

Detalles Bibliográficos
Autores principales: Strickler, John H., Rushing, Christel N., Niedzwiecki, Donna, McLeod, Abigail, Altomare, Ivy, Uronis, Hope E., Hsu, S. David, Zafar, S. Yousuf, Morse, Michael A., Chang, David Z., Wells, James L., Blackwell, Kimberly L., Marcom, P. Kelly, Arrowood, Christy, Bolch, Emily, Haley, Sherri, Rangwala, Fatima A., Hatch, Ace J., Nixon, Andrew B., Hurwitz, Herbert I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824108/
https://www.ncbi.nlm.nih.gov/pubmed/31675952
http://dx.doi.org/10.1186/s12885-019-6234-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824108/
https://www.ncbi.nlm.nih.gov/pubmed/31675952
http://dx.doi.org/10.1186/s12885-019-6234-8

Ejemplares similares